These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 17042972

  • 21. Effect of anti retroviral therapy (ART) on CD4 T lymphocyte count and the spectrum of opportunistic infections in HIV/AIDS in Manipur.
    Chitra Y, Urgen S, Dayananda I, Brajachand SN.
    J Commun Dis; 2009 Mar; 41(1):19-24. PubMed ID: 19886171
    [Abstract] [Full Text] [Related]

  • 22. HIV viral load supercedes CD4 count as best marker for predicting risk of AIDS and death.
    Baker R.
    BETA; 1996 Jun; ():9-11. PubMed ID: 11363652
    [Abstract] [Full Text] [Related]

  • 23. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y, Qiu ZF, Li TS, Han Y, Zuo LY, Xie J, Ma XJ, Liu ZY, Wang AX.
    Chin Med J (Engl); 2006 Oct 20; 119(20):1677-82. PubMed ID: 17097013
    [Abstract] [Full Text] [Related]

  • 24. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida.
    Enferm Infecc Microbiol Clin; 2009 Apr 20; 27(4):222-35. PubMed ID: 19246124
    [Abstract] [Full Text] [Related]

  • 25. Initiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States: comparing clinical practice to guidelines and literature evidence.
    Verweel G, Saavedra-Lozano J, van Rossum AM, Ramilo O, de Groot R.
    Pediatr Infect Dis J; 2006 Nov 20; 25(11):987-94. PubMed ID: 17072119
    [Abstract] [Full Text] [Related]

  • 26. Questions about HIV causing AIDS? Viral load and T-cell (CD4) counts: why they really matter.
    AIDS Treat News; 2001 May 11; (364):7-8. PubMed ID: 11569964
    [No Abstract] [Full Text] [Related]

  • 27. [Main clinical features and prognosis of AIDS patients with the predominance of thrombocytopenia].
    Wubuli M, Pan KJ, Sun XF, Aibaidula Y, Zhang YX.
    Zhonghua Yi Xue Za Zhi; 2012 May 22; 92(19):1314-6. PubMed ID: 22883117
    [Abstract] [Full Text] [Related]

  • 28. Recent developments in HIV treatment, Part 2.
    Boyle BA.
    AIDS Read; 2005 Jun 22; 15(6):277-9, 284. PubMed ID: 15962449
    [No Abstract] [Full Text] [Related]

  • 29. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.
    AIDS; 2008 Aug 20; 22(13):1583-8. PubMed ID: 18670217
    [Abstract] [Full Text] [Related]

  • 30. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M, Kaiser R, Däumer M, Fätkenheuer G, Rockstroh JK, Knechten H, Mitrenga D, Beerenwinkel N, Sagir A, Pfister H, Häussinger D.
    Dtsch Med Wochenschr; 2007 May 04; 132(18):977-82. PubMed ID: 17457780
    [Abstract] [Full Text] [Related]

  • 31. HIV coreceptor use in heavily treatment-experienced patients: does it take two to tangle?
    Melby T.
    Clin Infect Dis; 2007 Feb 15; 44(4):596-8. PubMed ID: 17243066
    [No Abstract] [Full Text] [Related]

  • 32. Anti-HIV agents. Should HAART begin right after an HIV diagnosis?
    TreatmentUpdate; 2009 Feb 15; 21(3):2-3. PubMed ID: 19630120
    [No Abstract] [Full Text] [Related]

  • 33. Early identification of seronegative human immunodeficiency virus type 1 infection with severe presentation.
    Chin BS, Lee SH, Kim GJ, Kee MK, Suh SD, Kim SS.
    J Clin Microbiol; 2007 May 15; 45(5):1659-62. PubMed ID: 17344360
    [Abstract] [Full Text] [Related]

  • 34. [AIDS].
    Oka S.
    Nihon Rinsho; 2003 Feb 15; 61 Suppl 2():276-80. PubMed ID: 12722228
    [No Abstract] [Full Text] [Related]

  • 35. Adding IL-2 to anti-HIV drugs increases CD4+ cell counts without raising HIV levels.
    AIDS Read; 2000 Sep 15; 10(9):522-3. PubMed ID: 11019440
    [No Abstract] [Full Text] [Related]

  • 36. [HIV associated encephalopathy after highly active antiretroviral therapy (HAART)].
    Kishida S.
    No To Shinkei; 2004 Apr 15; 56(4):301-10. PubMed ID: 15237721
    [No Abstract] [Full Text] [Related]

  • 37. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

  • 38. [HIV infections: further options for combination therapy].
    Hildegard K.
    Dtsch Med Wochenschr; 2003 Jul 11; 128(28-29):1523. PubMed ID: 12899165
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.
    J Infect Dis; 2007 Oct 01; 196(7):1044-52. PubMed ID: 17763327
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.